SYBLEU INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0185 USD | -25.25% |
|
-25.40% | -51.19% |
| Sales 2022 | 0.01 0.92 | Sales 2023 | 0.01 0.92 | Capitalization | 3.02M 237M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 * | - |
| Net Debt 2022 | 73.15K 5.74M | Net Debt 2023 | 474K 37.19M | EV / Sales 2023 | 298,725,376 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-16.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -25.25% | ||
| 1 week | -25.40% | ||
| Current month | -65.87% | ||
| 1 month | -76.58% | ||
| 3 months | -80.53% | ||
| 6 months | -62.85% | ||
| Current year | -51.19% |
1 week
0.02
0.03
1 month
0.020.06
Current year
0.010.15
1 year
0.010.29
3 years
0.010.29
5 years
0.010.29
10 years
0.010.29
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/05/24 | 0.0185 | -25.25% | 2,500 |
| 17/05/24 | 0.0248 | +12.50% | 269,826 |
Delayed Quote OTC Markets, May 22, 2024 at 08:59 pm
More quotes
SYBLEU Inc. is engaged in the acquisition, licensing and development of medical and veterinary applications. The Company is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The Company is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. It is also involved in the development of disposable medical devices. It has completed Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -51.19% | 196K | |
| +8.35% | 8.72B | |
| -16.83% | 4.79B | |
| +47.36% | 4.62B | |
| +1.74% | 3.82B | |
| +14.51% | 2.33B | |
| -26.23% | 2.2B | |
| +15.63% | 2.1B | |
| -34.87% | 2.04B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- SYBE Stock
